The trial with VALVOSOFT its disruptive, non-invasive, ultrasound treatment was proven to: be safe and feasible provide a sustained repair of the aortic valve improve quality of life
First Fully Implantable Electro-Physiological Cardiac Assistance Device FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER, a fully Implantable Cardiac Output
LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of
€6 million of further funds raised in addition to the €15 million in June Clinical trials expected in 2022 FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER